"МБАЛ „НКБ“ е водещ център у нас в диагностиката и лечението на съдовите заболявания. Тук се лекуват всички форми на исхемична болест на сърцето, заболявания на сърдечните клапи, остра и обострена хронична сърдечна недостатъчност, заболявания на миокарда и перикарда, както и на всички видове сърдечни аритмии. Болницата е водеща в страната при лечението на периферните съдови заболявания. В МБАЛ „НКБ“ работят утвърдени структури, като най-голямата клиника по кардиология в страната, единствената клиника по детска кардиология и детска кардиохирургия, уникалната структура по физикална кардиорехабилитация. Национална кардиологична болница разполага и със спешен кабинет."

During the past decade, MHAT National Cardiology Hospital EAD conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT National Cardiology Hospital EAD" #1 sponsor was "Bayer" with 4 trials, followed by "University National Heart Hospital" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored and "United Therapeutics" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT National Cardiology Hospital EAD" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Population Health Research Institute" with 1 trials as a collaborator and "Quintiles, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "MHAT National Cardiology Hospital EAD" are "Atrial Fibrillation" (4 trials), "Cardiovascular Diseases" (2 trials), "Connective Tissue Diseases" (2 trials), "Familial Primary Pulmonary Hypertension" (2 trials) and "Hypertension" (2 trials). Many other conditions were trialed in "MHAT National Cardiology Hospital EAD" in a lesser frequency.

Most popular intervention types in "MHAT National Cardiology Hospital EAD" are "Drug" (12 trials), "Other" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Edoxaban" (2 trials), "Ralinepag" (2 trials), "Apixaban" (1 trials) and "Apixaban matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "MHAT National Cardiology Hospital EAD" are 16 trials for "All" genders.

Currently, there are NaN active trials in "MHAT National Cardiology Hospital EAD". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in MHAT National Cardiology Hospital EAD, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in MHAT National Cardiology Hospital EAD, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".